McKenna's Pharmacology for Nursing, 2e

Index

A A fibres, 397, 398 Abacavir, 136, 137, 138

Adrenal medulla, 536, 537 Adrenaline, 297, 456, 458, 676, 864, 867, 871–872 Adrenergic agonists, 455–467 adults, 456 alpha- and beta-, 456–460 adverse effects, 459 care considerations, 459–460 contraindications and cautions, 459 drug–drug interactions, 459 pharmacokinetics, 458 subdivision of receptors, 456–457 therapeutic actions and indications, 457–458 alpha-specific, 462–465, 677–678 adverse effects, 463, 677 care considerations, 464–465, 677–678 contraindications and cautions, 463, 677 drug–drug interactions, 463, 677 pharmacokinetics, 463, 677 therapeutic actions and indications, 462–463, 677 beta-specific, 465–467 adverse effects, 466 care considerations, 466–467 contraindications and cautions, 466 drug–drug interactions, 466 pharmacokinetics, 465 therapeutic actions and indications, 465 children, 456 older adults, 456 sympathetic, 676–677 toxicity, 461–462 Adrenergic blocking agents, 469–485, 658, 714 adults, 471 alpha 1 -selective blocking agents, 469, 475–477 adverse effects, 476 care considerations, 476–477 contraindications and cautions, 476 drug–drug interactions, 476 pharmacokinetics, 476 therapeutic actions and indications, 476 antianginal agents, 716, 722–723 adverse effects, 723 care considerations, 723 contraindications and cautions, 723

therapeutic actions and indications, 722 beta 1 -selective adrenergic blocking agents, 469, 482–484 adverse effects, 483 care considerations, 484 contraindications and cautions, 483 drug–drug interactions, 483 pharmacokinetics, 483 therapeutic actions and indications, 482–483 children, 471 non-selective adrenergic blocking agents, 470–473 adverse effects, 472 care considerations, 473 contraindications and cautions, 471–472 drug–drug interactions, 472 pharmacokinetics, 471 therapeutic actions and indications, 470–471 non-selective alpha-adrenergic blocking agents, 469, 474–475 adverse effects, 474 care considerations, 474–475 contraindications and cautions, 474 drug–drug interactions, 474 pharmacokinetics, 474 therapeutic actions and indications, 474 non-selective beta-adrenergic blocking agents, 469, 477–480 adverse effects, 478–479 care considerations, 479–480 contraindications and cautions, 478 critical thinking scenario, 480–482 drug–drug interactions, 480 pharmacokinetics, 477–478 therapeutic actions and indications, 477 older adults, 471 Adrenergic receptors, 444, 448 sites, 470 Adrenergic response, 447–449 Adrenocortical agents, 536–548 adrenal glands, 537–538 adrenal crisis, 538 adrenal insufficiency, 538 controls, 537–538 duration of effect, 539 glucocorticoids, 536, 539–545 adverse effects, 543 care considerations, 544–545 contraindications and cautions, 543

Abatacept, 263, 264 Abciximab, 755, 758 Abiraterone, 212, 213 Abortifacients. See Prostaglandins Absence seizure, 352, 353, 355 Absorbable gelatine, 767, 769, 770 Absorption, 15, 20–22, 891 active transport, 15, 21 drug–drug or drug–alternative therapy interactions, 27 factors affecting, 21 first-pass effect, 21–22 passive diffusion, 16, 21 processes, 21 routes of administration, 20–21 Acarbose, 586, 588 ACE (angiotensin-converting-enzyme) inhibitors. See Angiotensin- converting enzyme (ACE) inhibitors Acetazolamide, 357, 361–362, 803, 805, 811 Acetic acids, 240, 246, 247 Acetylcholine, 297 receptor site, 432, 433 release, 451, 452 synthesis and storage, 451 Acetylcholinesterase, 444, 452, 487, 488 Acetylcysteine, 842, 859–860 Aciclovir, 127, 132, 133, 951, 956 Acid rebound, 896, 905 Acidification, 819, 821 Acidophilus, 962 Acromegaly, 521, 528 Actin, 642, 646 Action potential, 292, 294–295 Active immunity, 272, 273 Active transport, 15, 21 Acute myocardial infarction, 715 Adalimumab, 264, 266 Adapalene, 953 Adefovir, 127, 144, 145 A-delta fibres, 397, 398, 399 Adenosine, 698, 701, 703, 707 ADH (antiduretic hormone), 794, 798 Adiponectin, 572, 575 Adrenal cortex, 514, 536, 537

Adrenal dysfunction, 538 Adrenal glands, 537–538 adrenal crisis, 538 adrenal insufficiency, 538 controls, 537–538

drug–drug interactions, 723 pharmacokinetics, 722–723